Day 2 - December 11Thursday, 11 December 2025 - US/Eastern

Compounding GLP-1s like semaglutide and tirzepatide requires precision and rigorous safeguards. This session will explore:

• Best practices for dosing accuracy, ingredient quality, and stability, with a focus on semaglutide/tirzepatide protocols
• Cold-chain shipping validation and how warm-drug exposure impacts potency and patient safety
• Quality systems and automation tools to ensure consistency and reduce compliance risk

Scaling GLP-1 compounding creates new liabilities and regulatory decisions. This session will cover:

• Risk management strategies to prevent quality issues, minimize recalls, and protect against liability claims
• How QA/QC leaders and insurance advisors approach compliance in a fast-scaling environment
• The cost-benefit of multi-state licensure, including restrictive states such as California, South Carolina, Alabama, and Mississippi, and when national scale makes sense

An interactive closing session where attendees join small-group discussions to tackle today’s toughest regulatory and operational issues while also looking ahead to the future of compounding.

• Address compliance and quality challenges facing 503A and 503B pharmacies
• Share best practices to strengthen inspection readiness, operational safeguards, and patient safety
• Explore forward-looking priorities around regulatory shifts, payer dynamics, and market forces shaping 2026 and beyond